Educational content on VJOncology is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

Share this video  

ASCO 2026 | Prognostic model for rPFS in mCRPC incorporating ctDNA with established risk factors

Susan Halabi • 29 May 2026
ASCO 2026
Genitourinary Cancer Prostate Cancer

Susan Halabi, PhD, FSCT, FASA, FASCO, Duke Cancer Institute, Durham, NC, describes how established risk factors can be integrated with genomic alterations to classify patients with metastatic castrate-resistant prostate cancer (mCRPC) into risk groups. Previous models have successfully classified patients based on overall survival. Integration of genomic alterations to established risk factors improves risk stratification and has now been used to classify patients for radiographic progression-free survival (rPFS). This interview took place during the 2026 American Society of Clinical Oncology (ASCO) Meeting in Chicago, IL.

These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.

More from Susan Halabi

Clinical adoption of ctDNA assays into treatment decisions for mCRPC
0:46
Clinical adoption of ctDNA assays into treatment decisions for mCRPC
Susan Halabi • 29 May 2026
ctDNA prognostic model for rPFS in mCRPC: Alliance A031201 analysis
2:17
ctDNA prognostic model for rPFS in mCRPC: Alliance A031201 analysis
Susan Halabi • 30 May 2026
ctDNA models for predicting survival outcomes in mCRPC
1:32
ctDNA models for predicting survival outcomes in mCRPC
Susan Halabi • 2 Jun 2024
Targeting genetic variants in mCRPC to improve survival outcomes
1:17
Targeting genetic variants in mCRPC to improve survival outcomes
Susan Halabi • 2 Jun 2024

Related Videos

Improving emotional health assessment in patients with kidney cancer
0:57
Improving emotional health assessment in patients with kidney cancer
Eric Jonasch • 30 May 2026
Emotional health burden and unmet support needs in kidney cancer
2:19
Emotional health burden and unmet support needs in kidney cancer
Eric Jonasch • 30 May 2026
Background and rationale for the PROTEUS trial in HR LPC/LAPC
0:48
Background and rationale for the PROTEUS trial in HR LPC/LAPC
Mary-Ellen Taplin • 29 May 2026
Future directions in prostate cancer from the PROTEUS trial
1:08
Future directions in prostate cancer from the PROTEUS trial
Mary-Ellen Taplin • 29 May 2026
The content of VJOncology is intended for healthcare professionals